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Multiple endocrine neoplasia (MEN) types 1 and 2 are genetic diseases that are inherited as autosomal traits. The
major clinical manifestations of multiple endocrine neoplasia type 1 include the so-called ‘‘3 P’s’’: parathyroid,
pituitary, and pancreatic tumors, including gastroenteroneuroendocrine tumors. Genetic testing can be
performed on patients and the potential carriers of the menin gene mutation, but the genotype-phenotype
correlation in multiple endocrine neoplasia type 1 is less straightforward than multiple endocrine neoplasia type 2.
Most likely, the main advantage of genetic testing in MEN1 is to exclude from further studies those who are
negative for the genetic mutation if they belong to a family with a known history of MEN1. In Chile, we started
with rearranged during transfection proto-oncogene genetic testing (MEN2) 15 years ago. We carried out a
prophylactic total thyroidectomy to prevent medullary thyroid carcinoma in a three-year-old girl who presented
with microscopic medullary thyroid carcinoma. More than 90% of the individuals who tested positive using a
genetic test achieved a biochemical cure compared with only 27% of patients who receive a clinical diagnosis.
Mutations are mainly located in exon 11; the most common is C634W, rather than C634R. Hypertensive crisis was
the cause of death in three patients, and extensive distant metastases occurred in nine (including two patients
with multiple endocrine neoplasia type 2B) of 14 patients. Earlier recognition of medullary thyroid carcinoma and
the other features of the disease, especially pheochromocytoma, will improve the survival rate of patients with
multiple endocrine neoplasia.
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MULTIPLE ENDOCRINE NEOPLASIA TYPE 1
Multiple endocrine neoplasia type 1 (MEN1;MIM 131100)
is an autosomal dominant disease that predisposes indivi-
duals to develop parathyroid tumors (100% penetrance by
age 50), pancreatic islet cells tumors (30–75%), and pituitary
adenoma (10–60%) (1). Some patients may also develop
adrenal cortical tumors, carcinoid tumors, facial angiofi-
bromas, collagenomas and lipomas. They can also develop a
variable combination of more than 20 endocrine and
nonendocrine tumors (Table 1) (2,3).
A diagnosis of MEN1 should be considered when two of
the three principal MEN1 tumors affecting the parathyr-
oids, pancreatic islets, or anterior pituitary are present.
Familial MEN1 is diagnosed when at least one other first-
degree relative has one of the three main MEN1 tumors
(4).
MEN1 is a rare disease (the prevalence has been
estimated at 2–3/100,000) caused by a mutation in the
MEN1 gene (menin, MIM 613733) located on chromosome
11q13 and is characterized by a high penetrance (94% by the
fifth decade), high mortality, and no clear genotype-
phenotype correlation compared with MEN2. De novo
mutations have been described in up to 10% of cases (5–9).
The MEN1 gene consists of 10 exons that encode a 610-
amino acid protein, Menin, a nuclear protein that is
ubiquitously expressed. Menin is a tumor suppressor
protein and also plays a role in maintaining DNA stability
and gene regulation. Approximately 1133 germline muta-
tions in the MEN1 gene have been reported (9). The model
for tumorigenesis in familial MEN1, according to Knudson’s
‘‘two hits’’ theory, is that a mutated copy of MEN1 is
inherited at the germline level from an affected parent (first
hit), whereas the wild-type copy, which is inherited from
the healthy parent, is lost at the somatic level (second hit),
thereby resulting in a tumor. This mechanism is supported
by the observation that heterozygosity is lost, or allelic loss
occurs, when tumor DNA is compared with constitutive
DNA (2).
Genetic studies should be offered to patients who meet
the clinical criteria for MEN1 (sporadic or familial), their
asymptomatic relatives, and patients who do not meet
MEN1 criteria but have suspicious/atypical features that
are suggestive of MEN1. Genetic testing has enabled the
confirmation of clinical diagnosis, identification of asymp-
tomatic carriers who require screening for tumor detection
and early treatment and identification of family members
who do not have the MEN1 mutation and, therefore, do not
require further clinical examinations (10).
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Parathyroid tumors are the first manifestation of MEN1 in
more than 87% of patients; however, other tumors, like
pancreatic or pituitary adenoma, have also been reported as
the first manifestation (7).
Physical examination for dermal tumors should start in
childhood and be carried out periodically. Annual biochem-
ical screening is recommended after five years of age, and
tumor imaging should be performed less frequently
(Table 2) (4).
We started MEN1 genetic testing in 2001, initially with
one family, and then helped other researchers in Chile. We
gathered 22 patients from four families and three sporadic
cases, who were the youngest and the oldest patients
included (two patients). Genetic testing was performed on
two families (30 individuals), which identified 13 members
with the IVS9 + 1G.A mutation and three members with
the IVS6 + 1G.A mutation. Partial data from one family
was published in 2004 (11).
Table 3 shows the prevalence of each manifestation and
the age at diagnosis. Regarding hyperparathyroidism
(HPT), all three of the unaffected individuals were younger
than 24 years and the diagnosis was confirmed by genetic
testing. They were followed according to the criteria shown
in Table 2. Of the 22 other HPT individuals, the mean age at
onset was 39 years (19–86 years) and two patients were also
diagnosed with concomitant parathyroid carcinoma (at ages
of 31 and 75 years).
With regard to the other manifestations of MEN, their
prevalence does not differ significantly from other pub-
lished studies, with the exception of carcinoid tumors,
which our data indicate are more frequent even though all
of these cases occurred in the same family (7). One patient
had papillary thyroid microcarcinoma, a finding that could
be incidental. Regarding cutaneous manifestations, we
observed collagenoma, lipomas, and angiofibromas, but
not all patients were meticulously examined; therefore,
definitive conclusions cannot be reached.
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
MEN type 2 (MEN2) is an autosomal dominant syndrome
that affects approximately one in 30,000 individuals (4,12–14).
The major components of the syndrome are medullary
thyroid carcinoma (MTC), pheochromocytoma (PHEO) and
HPT. Germline mutations in the proto-oncogene RET (MIM
164761), located on chromosome 10q11.2, are responsible for
the three subtypes: MEN2A (80%;MIM 171400), MEN2B (5%;
MIM 162300) and familial MTC (FMTC, 15%; MIM 155240).
MTC commonly presents alongside the three subtypes, and
Table 1 - MEN1-related tumors (penetrance at age 40).
Organ/tumor Features %
Parathyroid hyperplasia/adenoma Multiglandular disease .90
Gastroenteropancreatic tract Gastrinoma 40
Insulinoma 10
Others (VIPoma, PPoma, SSoma, glucagonoma) 2
Nonfunctioning 20
Pituitary Prolactinoma 20
Acromegaly 5
GH/PRL 5
Nonfunctioning adenomas 17
Foregut carcinoids Thymic 2
Bronchial 2
Gastric enterochromaffin tumor 10
Adrenal gland Nonfunctioning 20–40
Pheochromocytoma ,1
Cortisol, aldosterone Rare
Skin tumors Facial angiofibromas 85
Collagenomas 70
Lipomas 30
Central nervous system Meningiomas 5–8
Ependymomas 1
Others Leyomiomas 10
VIP: vasoactive intestinal peptide. PP: pancreatic polypeptide. SS: somatostatin. GH: growth hormone. PRL: prolactin.
Table 2 - Clinical surveillance for subjects known to have MEN1 Adapted from (2,4).
Tumor Biochemical tests Age to begin (yr) Frequency
Hyperparathyroidism Serum calcium 5 Yearly
PTH 8 Yearly
Insulinoma Glycemia, fasting insulin, proinsulin 5 Yearly
Anterior pituitary PRL, IGF-1 5 Yearly
Gastrinoma Fasting and/or stimulated gastrin 20 Yearly
Tumor Imaging tests Age to begin (yr) Frequency
Enteropancreatic and carcinoid tumor Chest and Abdominal CT or MRI 20 Yearly to every 3–5 yr
Anterior pituitary Head MRI 5 Yearly to every 3–5 yr
Other enteropancreatic Somatostatin Receptor Scintigraphy (SRS)
Octreotide scan
Yet to be defined Yet to be defined
CT: computed tomography. MRI: magnetic resonance imaging.
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the risk of developing MTC is nearly 100%. Patients with
MEN2A/2B have a 30–50% risk of developing PHEO,
especially those who harbor mutations in codon 634, codon
A883F, and M918T (12–15). Diverse features differentiate
both subtypes: on one hand, only patients withMEN2A are at
risk of developing HPT and cutaneous lichen amyloidosis
(CLA) (10–30% and 12%, respectively) and only patients with
MEN2B have marfanoid habitus, mucosal neuromas on the
tongue, lips and subconjunctival areas and diffuse gang-
lioneuromas of the gastrointestinal tract (14). In FMTC,
affected patients suffer exclusively fromMTC; to prove that a
particular member of a family has FMTC, it is necessary to
demonstrate the absence of PHEO and HPT in two or more
generations within a family or provide evidence of an
identified RET mutation in families with FMTC (American
Thyroid Association) (13). Rarely, families with both MEN2
and Hirschsprung’s disease have been found to have MEN2-
specific codons 609, 611, 618, and 620 while also presenting
with the MEN2A or FMTC subtypes (15,16). MTC, when
presenting along with MEN2B, develops earlier and has a
more aggressive course than MTC in the other two subtypes.
During the first year of life, the classic features of MEN2B
may be lacking, so physicians must recognize themore subtle
features of this condition, such as the inability to cry and
constipation (17). Straightforward genotype-phenotype cor-
relations in MEN2 have also been described, and, as
expected, the aggressiveness of MTC is influenced by the
specific RET mutation. For instance, MTC has been con-
firmed using thyroidectomy specimens collected from
MEN2A patients as young as 15 months and in a 9-month-
old child with MEN2B (M918T); their conditions progressed
to N1 (TNM staging AJCC 2002) at 5 and 2.7 years old,
respectively (12,18–20). Therefore, identification of the
specific RET mutation that is present in at-risk patients
allows for effective clinical screening and optimal clinical and
surgical management. In 2009, after extensive review of the
literature, the American Thyroid Association (ATA) replaced
the consensus guidelines for diagnosis that were released in
2001 and developed a categorization system based on new
evidence in order to offer age-based recommendations for
performing prophylactic thyroidectomy, predict phenotypes
and to establish who should be screened for PHEO and HPT.
Table 4 shows the adapted ATA guidelines and other
guidelines (12,13).
We started RET genetic testing in 1997 and the most
important findings have been published (16,21,22). Sequ-
encing of the RET proto-oncogene was carried out in 60
sporadic MTC patients and 15 families with the MEN2
phenotype, totaling almost 200 individuals. In one family,
genetic testing is pending but their phenotype is MEN2A.
From the apparently sporadic patients, we found three new
MEN2 (probably FMTC) individuals (5%), one with codon
618, one with codon V804M, and another with codon S891A.
This percentage is within the range of occurrence of
apparently sporadic hereditary cases (4–7%) (23,24). Table 5
shows the main clinical features of 19 families. MEN2A
accounted for 73% of all cases, while FMTC and MEN2B
account for 21% and 6% of cases, respectively. The female-
male ratio was 1.2751. For patients who received genetic
testing (61 out of 63), the most common mutation was located
in exon 11 (62%), followed by exon 10 (25%), exon 16 (6%),
exon 14 (3.5%), and exon 15 (3.5%). In our population, the
C634W mutation was the most common (28%), followed by
mutations on exon 10 at codon C620R (21%) and the C634R
Table 3 - Prevalence of manifestations and age of diagnosis of MEN1 Chilean families.
Manifestation % (affected/total)
Median age at diagnosis, years
(range) N
Hyperparathyroidism 88 (22/25) 39 (19–86) 22
Pituitary tumor 28 (7/25) 40 (18–86) Acromegaly 3
Prolactinoma 1
GH/PRL 1
Nonfunctioning adenomas 2
Gastroenteropancreatic tumor 32 (8/25)* 35 (19–60) Gastrinoma 5
Nonfunctioning 2
enterochromaffin 3
Foregut carcinoids 16 (4/25){ 52 (23–67) Bronchial 3
Duodenal 2
Adrenal gland 24 (6/25) 47 (23–86) Nonfunctioning 4
Bilateral Hyperplasia 2
*Two patients presented with gastrinoma and pancreatic neuroendocrine tumor concomitantly.
{One patient had lung and duodenal carcinoids.
Table 4 - Recommendations for screening procedures and time of prophylactic thyroidectomy. Adapted from (12,13).
ATA Level D C B A
RET Mutation
codon
918, 883 634 609, 611, 618, 620, 630 768, 790, 804, 891
Age of prophylactic
thyroidectomy
ASAP or within the first year
of life
,5 years Consider surgery before age 5.
May delay surgery beyond
age of 5 years if stringent
criteria are met*
May delay surgery beyond
age
5 years if stringent criteria
are met*
Age of screening for PHEO Start at 8 years, then
annually
Start at 8 years, then
annually
Start at 20 years, then
annually
Start at 20 years, then
periodically
Age of screening for PHP Does not apply Start at 8 years, then
annually
Start at 20 years, then annually Start at 20 years, then
periodically
ASAP: as soon as possible.
*Normal annual basal/stimulated serum calcitonin level, normal annual neck ultrasound, less aggressive MTC family history and family preference.
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mutation (18%). These frequencies differ from the largest
published series, where C634R is the reported as the most
common mutation (13,15). We identified 56 patients with
MTC, with a median age of 28.5 years (range: 1–73 years), and
seven patients with CCH, with a median age of 7 years (range:
4–28 years). Interestingly, a V804M carrier who was operated
on at 28 years of age showed only CCH, demonstrating that
this mutation may have low penetrance in some cases (12,14).
The median preoperatory serum calcitonin level was 11 pg/
ml (range: 2.9–27 pg/ml) in patientswith CCHand 149 pg/ml
(range: 13–5549 pg/ml) in patients with MTC. There was a
high correlation between the preoperatory serum calcitonin
level and tumor size and stage (0.79 and 0.69 respectively,
p,0.005). Table 6 shows clinical outcomes and compares
biochemical cure, persistent disease, and death with the
method of diagnosis (e.g., genetic testing or clinical diagnosis):
14 patients died in total, and of these three died from
hypertensive crisis, two from surgical complications (one
was diagnosed by genetic testing) and nine from distant
metastases (including two out of the four patients with
MEN2B). Forty-nine patients are still alive: 36 are biochemi-
cally cured, 10 have persistent disease, two have not been
operated on yet and one has unknown condition that is
affecting his postoperatory calcitonin level. As expected,
patients who were prophylactically operated on were more
likely to be biochemical cured and demonstrated less persistent
disease states than those who were operated on after clinical
diagnosis. Regarding the other main features, PHEO was
present in 27% of patients, which presented bilaterally in most
patients with PHEO (70%), and the patients who developed
PHEO had a median age of 34 years (range: 26–47 years). HPT
was very uncommon (3%) and only seen in two patients with
the C634R mutation, as has been reported in other studies
(13,14,25). CLA was seen in three patients with the C634W
mutation, which is in agreement with other reports in the
literature (12,13,26). We did not find any cases of
Hirschsprung’s disease, a rarely associated condition that has
been described in patients with mutations in exon 10 (16,27,28).
We found four patients with the MEN2B phenotype; de novo
mutation was present in two of these patients and, retro-
spectively, both displayed the precocious symptoms of the
inability to cry and constipation during the first year of life.
In summary, the various types of MEN are inherited
autosomal dominant syndromes. Molecular biology techni-
ques have made it possible to identify the genes responsible
for causing MEN1 and 2. The identification of the carriers of
mutant MEN1 and 2 genes who are at risk of developing
these syndromes requires frequent biochemical screening
for the development of endocrine tumors. The identification
of those who are negative will save resources and reassure
both the patient and the family. Carriers of the genes
responsible for MEN2 should be advised to have thyroi-
dectomy in childhood, according with the ATA risk level of
the patient. Some cases of sporadic MTC are determined to
actually be MEN2 following RET proto-oncogene testing;
therefore, the routine application of this test is recom-
mended in all cases of apparent sporadic MTC.
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Table 5 - Clinical characteristics and RET mutations in families with MEN2.
Family
number
Individuals
analyzed/
mutated MTC/CCH ATA risk
Age of proband at
diagnosis (yr) of any
tumor Phenotype
Codon/protein
substitution PHEO (number) HPT (number)
1 26/11 8/3 C 42 MEN2A/CLA C634W 3 0
2 7/5 5/0 C 28 MEN2A C634W 2 0
3 3/1 1/0 C 43 MEN2A/CLA C634W 1 0
4 4/1 1/0 C 23 MEN2A C634R 1 1
5 6/5 5/0 C 38 MEN2A C634R 1 1
6 7/4 4/0 C 33 MEN2A C634R 1 0
7 3/1 1/0 C 26 MEN2A C634R 1 0
8 6/4 4/0 C 35 MEN2A C634G 2 0
9 9/5 5/0 C 29 MEN2A C634F 2 0
10 9/2 2/0 C 37 FMTC C634Y 0 0
11 2/2 2/0 B 40 FMTC C618R 0 0
12 17/6 5/1 B 50 FMTC C620R 0 0
13 11/7 5/2 B 18 MEN2A C620R 2 0
14 6/2 1/1 A 40 FMTC V804M 0 0
15 3/2 2/0 A 47 FMTC S891A 0 0
16 2/2 2/0 D 32 MEN2B M918T 1 0
17 3/1 1/0 D 14 MEN2B M918T 0 0
18 3/1 1/0 D 4 MEN2B M918T 0 0
19 2/2 2/0 pending 16 MEN2A pending 1 0
total 129/63 56/7 17 2
Table 6 - Outcome according to method of diagnosis and
serum calcitonin level.
Method of Diagnosis
Outcome Genetic Testing Clinical Total
Cured 28 8 36
% 90.3 27.6 60
Persistent 2 8 10
% 6.5 28 16.7
Dead 1 13 14
% 3.2 44.8 23
Total 31 29 60
% 100 100 100
Fisher’s exact test = 0.000.
Multiple endocrine neoplasia: the Chilean experience
Diaz RE and Wohllk N
CLINICS 2012;67(S1):7-11
10
REFERENCES
1. WermerP.Genetic aspects of adenomatosis of endocrine glands.Am JMed.
1954;16(3):363–71, http://dx.doi.org/10.1016/0002-9343(54)90353-8.
2. Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, et al. Multiple
endocrine neoplasia type one (MEN1): not only inherited endocrine
tumors. Genet Med. 2009;11(12):825–35, http://dx.doi.org/10.1097/
GIM.0b013e3181be5c97.
3. Wohllk N, Becker P, Ve´liz J, Pineda G. Multiple endocrine neoplasia: a
clinical model for applying molecular genetic techniques. Rev Med Chil.
2000;128(7):791–800.
4. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C,
et al. Guidelines for diagnosis and therapy of MEN type one and type 2.
J Clin Endocrinol Metab. 2001;86(12):5658–71, http://dx.doi.org/
10.1210/jc.86.12.5658.
5. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS,
Emmert-Buck MR, et al. Positional cloning of the gene for multiple
endocrine neoplasia-type 1. Science. 1997;276(5311):404–7, http://
dx.doi.org/10.1126/science.276.5311.404.
6. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al.
Identification of the multiple endocrine neoplasia type 1 (MEN1) gene.
The European Consortium on MEN1. Hum Mol Genet. 1997;6(7):1177–
83, http://dx.doi.org/10.1093/hmg/6.7.1177.
7. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, et al.
Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM.
1996;89(9):653–69.
8. Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS,
Harmsen WS, et al. Are patients with multiple endocrine neoplasia type I
prone to premature death? World J Surg. 2000;24(11):1437–41, http://
dx.doi.org/10.1007/s002680010237.
9. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res
Clin Endocrinol Metab. 2010;24(3):355–70, http://dx.doi.org/10.1016/
j.beem.2010.07.003.
10. Newey PJ, Thakker RV. Role ofmultiple endocrine neoplasia type 1 (MEN1)
mutational analysis in clinical practice. Endocr Pract. 2011;31(1):1–24.
11. Carrasco CA, Gonza´lez AA, Carvajal CA, Campusano C, Oestreicher E,
Arteaga E, et al. Novel intronic mutation of MEN1 gene causing familial
isolated primary hyperparathyroidism. J Clin Endocrinol Metab.
2004;89(8):4124–9, http://dx.doi.org/10.1210/jc.2003-032101.
12. Wohllk N, Schweizer H, Erlic Z, Schmid KW, Walz MK, Raue F, et al.
Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol
Metab. 2010;24(3):371–87, http://dx.doi.org/10.1016/j.beem.2010.02.001.
13. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al.
Medullary thyroid cancer: management guidelines of the American
Thyroid Association. Thyroid. 2009;19(6):565–612, http://dx.doi.org/
10.1089/thy.2008.0403.
14. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO,
et al. RET proto-oncogene: a review and update of genotype-phenotype
correlations in hereditary medullary thyroid cancer and associated
endocrine tumors. Thyroid. 2005;15(6):531–44, http://dx.doi.org/
10.1089/thy.2005.15.531.
15. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The
relationship between specific RET proto-oncogene mutations and disease
phenotype in multiple endocrine neoplasia type 2. International RET
mutation consortium analysis. JAMA. 1996;276(19):1575–9.
16. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al.
Risk profiles and penetrance estimations in multiple endocrine neoplasia
type 2A caused by germline RET mutations located in exon 10. Hum
Mutat. 2011;32(1):51–8, http://dx.doi.org/10.1002/humu.21385.
17. Brauckhoff M, Machens A, Hess S, Lorenz K, Gimm O, Brauckhoff K,
et al. Premonitory symptoms preceding metastatic medullary thyroid
cancer in MEN 2B: an exploratory analysis. Surgery. 2008;144(6):1044–50,
http://dx.doi.org/10.1016/j.surg.2008.08.028.
18. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ,
Roeher HD, et al. Early malignant progression of hereditary medullary
thyroid cancer. N Engl J Med. 2003;349(16):1517–25, http://dx.doi.org/
10.1056/NEJMoa012915.
19. Kaufman FR, Roe TF, Isaacs H Jr, Weitzman JJ. Metastatic medullary
thyroid carcinoma in young children with mucosal neuroma syndrome.
Pediatrics. 1982;70(2):263–7.
20. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF.
Application of genetic screening information to the management of
medullary thyroid carcinoma and multiple endocrine neoplasia type 2.
Endocrinol Metab Clin North Am. 1996;25(1):1–25, http://dx.doi.org/
10.1016/S0889-8529(05)70310-8.
21. Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF. [Germlinemutations of
the ret proto-oncogene in Chilean patients with hereditary and sporadic
medullary thyroid carcinoma]. Rev Med Chil. 2001;129(7):713–8.
22. Milos IN, Frank-Raue K, Wohllk N, Maia AL, Pusiol E, Patocs A, et al.
Age-related neoplastic risk profiles and penetrance estimations in multi-
ple endocrine neoplasia type 2A caused by germ line RET Cys634Trp
(TGC.TGG) mutation. Endocr Relat Cancer. 2008;15(4):1035–41, http://
dx.doi.org/10.1677/ERC-08-0105
23. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H,
et al. Relevance of RET proto-oncogene mutations in sporadic medullary
thyroid carcinoma. J Clin Endocrinol Metab. 1996;81(10):3740–5, http://
dx.doi.org/10.1210/jc.81.10.3740.
24. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET
genetic screening in patients with medullary thyroid cancer and their
relatives: experience with 807 individuals at one center. J Clin Endocrinol
Metab. 2007;92(12):4725–9, http://dx.doi.org/10.1210/jc.2007-1005.
25. Punales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in
multiple endocrine neoplasia type 2: variable clinical features and
clinical outcome. J Clin Endocrinol Metab. 2003;88(6):2644–9, http://
dx.doi.org/10.1210/jc.2002-021422.
26. Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D,
et al. Frequent association between MEN 2A and cutaneous lichen
amyloidosis. Clin Endocrinol. 2003;59(2):156–61, http://dx.doi.org/
10.1046/j.1365-2265.2003.01782.x.
27. Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET
proto-oncogene in multiple endocrine neoplasia type two and
Hirschsprung’s disease. N Engl J Med. 1996;335(13):943–51, http://
dx.doi.org/10.1056/NEJM199609263351307.
28. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, et al.
Association of multiple endocrine neoplasia type 2 and Hirschsprung
disease. J Intern Med. 1998;243(19):515–20, http://dx.doi.org/10.1046/
j.1365-2796.1998.00332.x.
CLINICS 2012;67(S1):7-11 Multiple endocrine neoplasia: the Chilean experience
Diaz RE and Wohllk N
11
